Catalysis of the CC-1065 and duocarmycin DNA alkylation reaction: DNA binding induced conformational change in the agent results in activation
Dale L. Boger(Scripps Research Institute), R. M. Garbaccio(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 89
Related Papers
The importance of synthetic chemistry in the pharmaceutical industry
|Science|2019|650
CC-1065 and the Duocarmycins: Synthetic Studies
|Chemical Reviews|1997|267
Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2<i>S</i>)-4-(2,5-Difluorophenyl)-<i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-<i>N</i>-methyl-2-phenyl-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer
|Journal of Medicinal Chemistry|2008|156
Concise Asymmetric Syntheses of Radicicol and Monocillin I
|Journal of the American Chemical Society|2001|144
Shape-Dependent Catalysis: Insights into the Source of Catalysis for the CC-1065 and Duocarmycin DNA Alkylation Reaction
|Accounts of Chemical Research|1999|143